Rising Demand for Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Key Players, Growth Analysis during 2021-2027

The global poly (ADP-Ribose) polymerase (PARP) inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Poly polymerase term is derived from PARP or the poly (adenosine diphosphate [ADP] -ribose) polymerase. It is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain (the PAR chain) and transfers them to the target proteins. This supports to restore DNA when it is damaged. DNA can be damaged by many factors, including exposure to UV rays, radiation, some anti-cancer drugs, or other substances in the environment. PARP inhibitors block an enzyme critical to the repair of single stranded breaks in DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency in other DNA repair pathways. The major factor attributable to the market growth includes the growing prevalence of cancer all over the globe. For instance, ovarian cancer is the second most common gynecologic cancer in the US.

To Request a Sample of our Report on Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market: https://www.omrglobal.com/request-sample/poly-adp-ribose-polymerase-parp-inhibitors-market

The American Cancer Society (ACS) estimates that in 2022, there will be nearly 19,880 women receiving a new diagnosis of ovarian cancer in the US. Combination therapies, specifically those including checkpoint inhibitors, are poised to be introduced in the first-line setting to target major unmet needs including overcoming tumor resistance, improving progression-free survival, and maintaining the quality of life. PARP inhibitors play an effective maintenance role in current cancer-combating strategies with its superior effect to that of existing ovarian cancer treatment. Currently, Talazoparib and Veliparib are in Phase III clinical trials and Rucaparib, Olaparib and Niraparib are approved PARP drugs which are currently present in the market for ovarian cancer treatment. PARP inhibitors improve progression-free survival in women with recurrent ovarian cancer, sensitive to platinum.

Market Coverage

· The market number available for - 2020-2027

· Base year- 2020

· Forecast period- 2021-2027

Segment Covered-

· By Drugs

· By Indication

Regions covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape: Pfizer Inc., AstraZeneca plc and GlaxoSmithKline plc, among others.

(Get 15% Discount on Buying this Report)

A full Report of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market is Available @ https://www.omrglobal.com/industry-reports/poly-adp-ribose-polymerase-parp-inhibitors-market

Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Report by Segment

By Drugs

· Talazoparib

· Veliparib

· Olaparib

· Others

By Indication

· Ovarian Cancer

· Fallopian Tube Cancer

· Breast Cancer

· Others

Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.